These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 2093526

  • 1. Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients.
    Granolleras C, Branger B, Deschodt G, Shaldon S, Nonnast-Daniel B, Pollok M.
    Contrib Nephrol; 1990; 82():49-54. PubMed ID: 2093526
    [No Abstract] [Full Text] [Related]

  • 2. Reasons for differences in dose requirements of recombinant human erythropoietin in haemodialysis patients.
    Scigalla P, Messinger D, Wieczorek L.
    Contrib Nephrol; 1990; 82():55-64. PubMed ID: 2093527
    [No Abstract] [Full Text] [Related]

  • 3. Weekly subcutaneous erythropoietin maintains hematocrit in chronic hemodialysis patients.
    Parker KP, Sands JM.
    J Am Soc Nephrol; 1993 Apr; 3(10):1717-8. PubMed ID: 8318688
    [No Abstract] [Full Text] [Related]

  • 4. Crossover comparison of intravenous and subcutaneous recombinant human erythropoietin in a small haemodialysis unit.
    Balkovetz DF, Frazier C, Sanders PW.
    Nephrol Dial Transplant; 1998 Nov; 13(11):2979-80. PubMed ID: 9829525
    [No Abstract] [Full Text] [Related]

  • 5. [Utility of recombinant human erythropoietin on the anemia of elderly hemodialysis patients].
    Ueyama H, Nakahashi H, Sawanishi K, Kuze M, Ono T.
    Hinyokika Kiyo; 1992 Dec; 38(12):1429-35. PubMed ID: 1288237
    [Abstract] [Full Text] [Related]

  • 6. Monitoring erythropoietin therapy for anaemia of chronic renal failure by serum erythropoietin assays.
    Marsden JT, Sherwood RA, Hillis A, Peters TJ.
    Ann Clin Biochem; 1993 Mar; 30 ( Pt 2)():205-6. PubMed ID: 8466156
    [No Abstract] [Full Text] [Related]

  • 7. Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease. Ad Hoc Committee for the National Kidney Foundation.
    Am J Kidney Dis; 1989 Sep; 14(3):163-9. PubMed ID: 2672796
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis.
    Ongkingco JR, Ruley EJ, Turner ME, Fragale MR.
    Am J Nephrol; 1994 Sep; 14(1):14-8. PubMed ID: 8017476
    [Abstract] [Full Text] [Related]

  • 10. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.
    Boran M, Dalva I, Yazicioğlu A, Cetin S.
    Nephron; 1993 Sep; 63(1):113-4. PubMed ID: 8446239
    [No Abstract] [Full Text] [Related]

  • 11. Erythropoietin for anemia of renal failure in sickle cell disease.
    Steinberg MH.
    N Engl J Med; 1991 May 09; 324(19):1369-70. PubMed ID: 1759999
    [No Abstract] [Full Text] [Related]

  • 12. Role of blood rheology in the pathogenesis of hypertension of hemodialysis patients treated for renal anemia with recombinant human erythropoietin.
    Baldamus CA, Steffen AM, Brunner R, Pollok M.
    Contrib Nephrol; 1990 May 09; 82():79-85. PubMed ID: 2093531
    [No Abstract] [Full Text] [Related]

  • 13. Erythropoietin in continuous ambulatory peritoneal dialysis: experience with subcutaneous administration.
    Eisele G, Bailie GR, Clement C, Wong E.
    Perit Dial Int; 1992 May 09; 12(1):34-6. PubMed ID: 1543777
    [Abstract] [Full Text] [Related]

  • 14. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
    Uthayanaka Y, Jirajan B, Krairithichai U, Jantavanich N.
    Southeast Asian J Trop Med Public Health; 1993 Sep 09; 24(3):577-82. PubMed ID: 8160072
    [Abstract] [Full Text] [Related]

  • 15. Subcutaneous erythropoietin: a comparison of daily and thrice weekly administration.
    Granolleras C, Branger B, Shaldon S, Nonnast-Daniel B, Koch KM, Pollok M, Baldamus CA.
    Contrib Nephrol; 1991 Sep 09; 88():144-8; discussion 149-51. PubMed ID: 2040176
    [No Abstract] [Full Text] [Related]

  • 16. Human recombinant erythropoietin in the treatment of anaemia in chronic haemodialysis patients.
    Sulková S, Kvasnicka J, Kasl M, Kozlová J, Podrouzek P, Bartûsková J, Válek A.
    Czech Med; 1990 Sep 09; 13(2-3):98-106. PubMed ID: 2245762
    [Abstract] [Full Text] [Related]

  • 17. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 Sep 09; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 18. Beneficial and adverse effects of correction of anaemia by recombinant human erythropoietin in patients on maintenance haemodialysis.
    Grützmacher P, Bergmann M, Weinreich T, Nattermann U, Reimers E, Pollok M.
    Contrib Nephrol; 1988 Sep 09; 66():104-13. PubMed ID: 3292143
    [No Abstract] [Full Text] [Related]

  • 19. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration.
    Besarab A, Flaharty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F, Caro J, Morris E.
    J Am Soc Nephrol; 1992 Mar 09; 2(9):1405-16. PubMed ID: 1627763
    [Abstract] [Full Text] [Related]

  • 20. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients.
    Lago M, Pérez-García R, García de Vinuesa MS, Anaya F, Valderrábano F.
    Nephron; 1996 Mar 09; 72(4):723-4. PubMed ID: 8730458
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.